Semax

Updated June 29, 2026

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the first four amino acids of ACTH (adrenocorticotropic hormone), with a modified C-terminal sequence that confers metabolic stability. It was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s as a potential neuroprotective agent. It received approval in Russia and Ukraine for clinical use in stroke recovery, transient ischaemic attacks, peptic ulcer treatment, and cognitive impairment — giving it one of the longer legitimate medical track records of any peptide in the nootropic space.

The primary mechanism most relevant to cognitive enhancement is BDNF (brain-derived neurotrophic factor) upregulation. BDNF is the main neurotrophic protein supporting the survival, growth, and differentiation of neurons, and is strongly associated with learning, memory consolidation, and resilience against neurodegeneration. Semax increases BDNF expression in multiple brain regions including the prefrontal cortex and hippocampus. It also upregulates NGF (nerve growth factor), increases dopaminergic and serotonergic tone in the striatum, and modulates the RAAS system to improve cerebral blood flow.

Users and clinical subjects consistently report improved focus, faster mental processing, enhanced working memory, and heightened motivation. The onset is notably rapid — many effects are perceptible within 20 to 40 minutes of administration and last 8 to 12 hours. Unlike many stimulants, semax does not produce jitteriness, cardiovascular stimulation, or a marked crash. It appears to enhance the quality of cognitive engagement rather than simply raising arousal. Anxiolytic effects are also reported at higher doses, likely via serotonin modulation.

Neuroprotective applications have the strongest clinical documentation. Multiple Russian trials demonstrate reduced neurological deficit, faster recovery of function, and improved outcomes in stroke patients when semax is administered within the first day of stroke onset. The mechanism involves reduced neuroinflammation, inhibition of apoptotic signalling in penumbral neurons, and enhanced neurotrophic support to surviving tissue. These acute neuroprotective findings are distinct from the chronic cognitive enhancement use, but both likely draw on the same BDNF and dopamine-modulating mechanisms.

Semax is administered intranasally or subcutaneously — intranasal is the most common route for cognitive use, with 0.5 to 1 mg per day as the typical dose. A common protocol is 200 to 300 mcg per nostril once or twice daily. It is not orally bioavailable. It is a prescription drug in Russia and sold as a research chemical elsewhere. Quality and concentration consistency vary significantly between sources. This is general information, not medical advice.